Sun to take Taro private after sweetened buy-out offer
This article was originally published in Scrip
India's Sun Pharmaceutical Industries is set to take Taro Pharmaceutical Industries private after a sweetened offer of $39.50 per share to acquire the remaining 34% not held by Sun in Taro was blessed by the Israeli firm's board. Sun expects to delist Taro from the New York Stock Exchange once the current proposal is executed.
You may also be interested in...
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.